Allecra Therapeutics

Allecra Therapeutics is a French biotech addressing the global crisis of antimicrobial resistance (AMR) through the development of novel antibiotic combinations. Its lead asset, cefepime/enmetazobactam, has demonstrated superiority over the standard of care (piperacillin-tazobactam) in a pivotal Phase 3 trial for complicated urinary tract infections (cUTIs), positioning it for near-term regulatory submissions in the US and EU. Backed by a seasoned management team and European life science investors, the company is navigating the challenging but critically important antibiotic development landscape with a late-stage, high-need product candidate.

Development of novel beta-lactamase inhibitors (e.g., enmetazobactam) designed to be combined with established beta-lactam antibiotics to overcome resistance mechanisms in bacteria, particularly Extended-Spectrum Beta-Lactamases (ESBLs).

The company competes in the novel antibiotic/BLI combination space against other biotechs and pharma companies (e.g., Venatorx/GSK with cefepime/taniborbactam, Shionogi with cefiderocol). Its direct comparator and competitor is the widely used piperacillin-tazobactam, against which it has shown superiority, but which benefits from entrenched use and lower cost.